Novartis AG
Novartis AG (NVS) is a large, diversified Swiss pharmaceutical group focused on developing, manufacturing and commercialising prescription medicines, generics and biosimilars. With a market capitalisation around $277.45 billion, the company combines an R&D-led portfolio of patented therapies with a generics and biosimilars arm (Sandoz). Investors often look at Novartis for its sizeable pipeline, steady cash generation and established global commercial footprint, particularly in oncology, ophthalmology and specialised medicines. Key things to watch are clinical-trial progress, patent expiries, regulatory decisions and pricing pressure in major markets. Novartis pays a dividend and aims for returns from both organic growth and selective portfolio optimisation, but values can fall as well as rise. This is general, educational information and not personalised advice; consider your own circumstances and risks before making investment decisions.
Why It's Moving
Novartis ianalumab shines in Phase III, extending ITP control with just four doses amid oncology growth push.
Novartis reported breakthrough Phase III data on December 9 showing ianalumab significantly prolongs disease control in immune thrombocytopenia patients, maintaining benefits 2.8 times longer than placebo with minimal dosing.[1] This advance bolsters the company's innovative pipeline, complementing raised long-term sales forecasts for blockbusters like Kisqali and Scemblix through 2030.[2]
- Ianalumab (9 mg/kg) plus eltrombopag extended ITP control by 45%, with 62% of patients sustaining response, reducing treatment burden.[1]
- Raised 2030 sales outlook to 5-6% annual growth, boosting Kisqali peak to over $10B and Scemblix to over $4B, signaling oncology dominance despite generic pressures.[2]
- Q3 results reaffirmed FY 2025 guidance with robust sales growth and milestones like FDA approval for Rhapsido in CSU.[3]
Novartis ianalumab shines in Phase III, extending ITP control with just four doses amid oncology growth push.
Novartis reported breakthrough Phase III data on December 9 showing ianalumab significantly prolongs disease control in immune thrombocytopenia patients, maintaining benefits 2.8 times longer than placebo with minimal dosing.[1] This advance bolsters the company's innovative pipeline, complementing raised long-term sales forecasts for blockbusters like Kisqali and Scemblix through 2030.[2]
- Ianalumab (9 mg/kg) plus eltrombopag extended ITP control by 45%, with 62% of patients sustaining response, reducing treatment burden.[1]
- Raised 2030 sales outlook to 5-6% annual growth, boosting Kisqali peak to over $10B and Scemblix to over $4B, signaling oncology dominance despite generic pressures.[2]
- Q3 results reaffirmed FY 2025 guidance with robust sales growth and milestones like FDA approval for Rhapsido in CSU.[3]
Stock Performance Snapshot
Analyst Rating
Analysts suggest keeping Novartis stock for now, with a target price that is lower than the current price.
Financial Health
Novartis is performing exceptionally well, showing strong profits, cash flow, and revenue growth.
Dividend
Novartis AG offers a dividend yield of 3.01%, making it a decent option for those seeking dividend income. If you invested $1000 you would be paid $30.10 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NVS
Global Pharma Titans | Brazil Healthcare Investment
Brazil's large and innovative pharmaceutical market presents a significant area of interest for those looking at global healthcare trends. This basket provides exposure to leading US and EU-listed pharmaceutical and biotech companies with substantial operations, partnerships, or sales within Brazil.
Published: October 16, 2025
Explore BasketHealthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: October 14, 2025
Explore BasketPharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: October 12, 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: August 5, 2025
Explore BasketPharma's Pricing Pressure
In response to a presidential ultimatum for 17 drug makers to slash U.S. prices, the pharmaceutical industry faces a major regulatory challenge. This event creates a potential investment opportunity in companies positioned to gain from the pricing disruption, including generic manufacturers.
Published: August 3, 2025
Explore BasketBeyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: August 1, 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketThe Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: July 2, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketWhy You’ll Want to Watch This Stock
R&D‑led pipeline
Novartis invests heavily in research, so trial outcomes and approvals can be catalysts — though clinical setbacks are possible and can affect valuation.
Global footprint
A wide geographic reach and diversified product mix help revenue resilience, but exposure to pricing and regulatory changes in major markets remains a risk.
Cash flow & returns
Strong cash generation can support dividends and strategic deals, yet past performance is not a guide to future returns and outcomes may vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
